PTC 10-Q Details $2.13B Cash, $29.0M Nine-Month Profit After $111M ST-920 Charge
PTCT is trading near its 52-week low of $58.8 (5.4% above the low).
Summary
PTC's Q3 10-Q shows $2.13 billion in cash and marketable securities and a $51.7 million quarterly loss driven by the $111.0 million ST-920 charge and a $19.3 million debt-extinguishment loss, with nine-month operating cash flow of $44.8 million.
Key Events · Earnings and Guidance · PTCT
-
Q3 Loss Driven by ST-920 Charge
Net loss was $51.7 million, or $0.62 per share, including a $111.0 million acquired IPR&D charge for ST-920 and a $19.3 million loss on debt extinguishment.
-
Cash Position $2.13 Billion
Cash, cash equivalents and marketable securities totaled $2.13 billion at September 30, 2026; management says this funds operations for at least the next twelve months.
-
Sephience Sales Scale to $457.7M
Nine-month Sephience net product revenue reached $457.7 million versus $19.6 million a year earlier, lifting total nine-month product revenue to $740.3 million from $402.7 million.
-
Operating Cash Flow Falls to $44.8M
Nine-month operating cash flow was $44.8 million versus $745.5 million in 2025, which had included the $1.0 billion Novartis upfront payment.
Analysis · PTCT · Life Sciences
The 10-Q fills in the balance sheet behind this morning's 8-K: $2.13 billion of cash, cash equivalents and marketable securities at September 30, 2026, which management says funds operations for at least the next twelve months. Accounting, not cash burn, drives the quarter's $51.7 million net loss — the $111.0 million upfront payment for ST-920 (expensed immediately as acquired IPR&D) plus a $19.3 million loss on extinguishing the remaining 2026 convertible notes. Strip those out and the commercial business is close to breakeven, with Sephience product sales of $457.7 million over nine months versus $19.6 million a year ago. Cash generation tells the offsetting story: nine-month operating cash flow fell to $44.8 million from $745.5 million, because last year included the $1.0 billion Novartis upfront. Also new here: three directors adopted 10b5-1 sale plans during the quarter, adding to the insider distribution already visible over the past 90 days.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PTCT was trading at $62.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $58.80 to $90.87. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.